Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Arovella Therapeutics LimitedTelephone
61.3.9824.5254
Address
Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053
Description
Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.08 - 0.2
Trade Value (12mth)
AU$62,749.00
1 week
5.71%
1 month
19.35%
YTD
54.17%
1 year
103.3%
All time high
14.78
EPS 3 yr Growth
-38.80%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-92.10%
ROIC
-116.60%
Interest Coverage
-1,247.60
Quick Ratio
6.40
Shares on Issue (Fully Dilluted)
978m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
29 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 October 24 |
AusBioInvest Presentation
×
AusBioInvest Presentation |
25 October 24 |
Arovella receives R&D tax rebate of $3.0 million
×
Arovella receives R&D tax rebate of $3.0 million |
24 October 24 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
24 October 24 |
Notice Under Section 708A
×
Notice Under Section 708A |
18 October 24 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
18 October 24 |
Notice Under Section 708A
×
Notice Under Section 708A |
16 October 24 |
Investor Presentation
×
Investor Presentation |
16 October 24 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
16 October 24 |
Notice Under Section 708A
×
Notice Under Section 708A |
14 October 24 |
Clinical Advisory Board established
×
Clinical Advisory Board established |
09 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
07 October 24 |
Notification regarding unquoted securities - ALA
×
Notification regarding unquoted securities - ALA |
01 October 24 |
Release of Shares from Escrow
×
Release of Shares from Escrow |
19 September 24 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
19 September 24 |
Notification regarding unquoted securities - ALA
×
Notification regarding unquoted securities - ALA |
18 September 24 |
Change in substantial holding
×
Change in substantial holding |
18 September 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
18 September 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
12 September 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
12 September 24 |
Updated Investor Webinar Presentation
×
Updated Investor Webinar Presentation |
11 September 24 |
2024 ESG Report
×
2024 ESG Report |
10 September 24 |
ALA presents at Cell and Gene Therapy World Asia Conference
×
ALA presents at Cell and Gene Therapy World Asia Conference |
22 August 24 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
22 August 24 |
Appendix 4G
×
Appendix 4G |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.